Clinical Trial Update: Long-Term Effect of 10 mg Versus 20 mg Rimonabant in Overweight or Obese Patients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing 10 mg vs 20 mg rimonabant in overweight/obese patients was terminated after long-term assessment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• Rimonabant (rimonabant)

Snippet

Sponsor: Sanofi | Conditions: Obesity, Weight Loss | Phase 3 | Status: TERMINATED